Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Drugs in Development, 2021

November 2021 | 256 pages | ID: N6D35228749CEN
Global Markets Direct

Abstracts

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I - Drugs In Development, 2021, provides an overview of the Neurofibromatoses Type I (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type I (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 6, 2 and 6 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Neurofibromatoses Type I (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type I (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Neurofibromatoses Type I (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Neurofibromatoses Type I (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type I (Genetic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type I (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type I (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Neurofibromatoses Type I - Overview
Neurofibromatoses Type I - Therapeutics Development
Neurofibromatoses Type I - Therapeutics Assessment
Neurofibromatoses Type I - Companies Involved in Therapeutics Development
Neurofibromatoses Type I - Drug Profiles
Neurofibromatoses Type I - Dormant Projects
Neurofibromatoses Type I - Discontinued Products
Neurofibromatoses Type I - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Advenchen Laboratories LLC, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by AlloMek Therapeutics, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by AstraZeneca Plc, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Bristol-Myers Squibb Co, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Eli Lilly and Co, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Fochon Pharmaceutical Ltd, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Healx Ltd, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by NFlection Therapeutics Inc, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Novartis AG, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Ono Pharmaceutical Co Ltd, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Pfizer Inc, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Sino Biopharmaceutical Ltd, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by SpringWorks Therapeutics Inc, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Vyriad Inc, 2021
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021